Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
March 31 2020 - 4:07PM
Edgar (US Regulatory)
|
|
OMB
APPROVAL
|
|
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB
Number: 3235-0167
Expires:
November 30, 2010
Estimated
average burden hours per response . . . . . . . . . . 1.50
|
FORM
15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File Number 000-54856
OWC
PHARMACEUTICAL RESEARCH CORP.
|
(Exact
name of registrant as specified in its charter)
|
2
Ben Gurion St., Ramat Gan
Israel
5257334
+972-72-260-8004
|
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
|
Common
Stock, par value $0.0001
|
(Title
of each class of securities covered by this Form)
|
None
|
(Titles
of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
|
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file
reports:
|
Rule
12g-4(a)(1)
|
[X]
|
|
Rule
12g-4(a)(2)
|
[ ]
|
|
Rule
12h-3(b)(1)(i)
|
[X]
|
|
Rule
12h-3(b)(1)(ii)
|
[ ]
|
|
Rule
15d-6
Rule
15d-22(b)
|
[ ]
[ ]
|
Approximate
number of holders of record as of the certification or notice date: 224
Pursuant
to the requirements of the Securities Exchange Act of 1934, OWC Pharmaceutical Research Corp. has caused this certification/notice
to be signed on its behalf by the undersigned duly authorized person.
Date:
|
March
31, 2020
|
|
By:
|
|
|
|
|
|
Zvi
Riterband, Chief Executive Officer
|
Instruction:
This form is required by Rules 12g-4, 12h-3, 15d-6 and Rule 15d-22 of the General Rules and Regulations under the Securities Exchange
Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It
may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person
signing the form shall be typed or printed under the signature.
SEC2069(02-08)
|
Persons
who respond to the collection of information contained in this form are not required to respond unless the form displays a
currently valid OBM control number.
|
|
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Jul 2024 to Aug 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2023 to Aug 2024